The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Open accessAbstract
Background: The role of transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma (HCC) is unconfirmed. This study aimed to assess the efficacy and safety of immune checkpoint inhibitors (ICIs) plus anti-vascular endothelial growth factor (anti-VEGF) antibody/tyrosine kinase inhibitors (TKIs) with or without TACE as first-line treatment for advanced HCC. Methods: This nationwide, multicenter, retrospective cohort study included advanced HCC patients receiving either TACE with ICIs plus anti-VEGF antibody/TKIs (TACE-ICI-VEGF) or only ICIs plus anti-VEGF antibody/TKIs (ICI-VEGF) from January 2018 to December 2022. The study design followed the target trial emulation framework with stabilized inverse probability of treatment weighting (sIPTW) to minimize biases. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), objective response rate (ORR), and safety. The study is registered with ClinicalTrials.gov, NCT05332821. Findings: Among 1244 patients included in the analysis, 802 (64.5%) patients received TACE-ICI-VEGF treatment, and 442 (35.5%) patients received ICI-VEGF treatment. The median follow-up time was 21.1 months and 20.6 months, respectively. Post-application of sIPTW, baseline characteristics were well-balanced between the two groups. TACE-ICI-VEGF group exhibited a significantly improved median OS (22.6 months [95% CI: 21.2-23.9] vs 15.9 months [14.9-17.8]; P < 0.0001; adjusted hazard ratio [aHR] 0.63 [95% CI: 0.53-0.75]). Median PFS was also longer in TACE-ICI-VEGF group (9.9 months [9.1-10.6] vs 7.4 months [6.7-8.5]; P < 0.0001; aHR 0.74 [0.65-0.85]) per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. A higher ORR was observed in TACE-ICI-VEGF group, by either RECIST v1.1 or modified RECIST (41.2% vs 22.9%, P < 0.0001; 47.3% vs 29.7%, P < 0.0001). Grade ≥3 adverse events occurred in 178 patients (22.2%) in TACE-ICI-VEGF group and 80 patients (18.1%) in ICI-VEGF group. Interpretation: This multicenter study supports the use of TACE combined with ICIs and anti-VEGF antibody/TKIs as first-line treatment for advanced HCC, demonstrating an acceptable safety profile. Funding: National Natural Science Foundation of China, National Key Research and Development Program of China, Jiangsu Provincial Medical Innovation Center, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, and Nanjing Life Health Science and Technology Project.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
Self-citationLocoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Self-citationSangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.005 · Cited by 365
Self-citation
Cited by
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Self-citation
Metadata
- Authors
- Jin, Z.-C., Chen, J.-J., Zhu, X.-L., Duan, X.-H., Xin, Y.-J., Zhong, B.-Y., Chen, J.-Z., Tie, J., Zhu, K.-S., Zhang, L., Huang, M., Piao, M.-J., Li, X., Shi, H.-B., Liu, R.-B., Xu, A.-B., Ji, F., Wu, J.-B., Shao, G.-L., Li, H.-L., Huang, M.-S., Peng, Z.-Y., Ji, J.-S., Yuan, C.-W., Liu, X.-F., Hu, Z.-C., Yang, W.-Z., Yin, G.-W., Huang, J.-H., Ge, N.-J., Qi, X., Zhao, Y., Zhou, J.-W., Xu, G.-H., Tu, Q., Lin, H.-L., Zhang, Y.-J., Jiang, H., Shao, H.-B., Su, Y.-J., Chen, T.-S., Shi, B.-Q., Zhou, X., Zhao, H.-T., Zhu, H.-D., Ren, Z.-G., Teng, G.-J., Jin, Z.-C., Chen, J.-J., Zhu, X.-L., Duan, X.-H., Xin, Y.-J., Zhong, B.-Y., Chen, J.-Z., Tie, J., Zhu, K.-S., Zhang, L., Huang, M., Piao, M.-J., Li, X., Shi, H.-B., Liu, R.-B., Xu, A.-B., Ji, F.-P., Wu, J.-B., Shao, G.-L., Li, H.-L., Huang, M.-S., Peng, Z.-Y., Ji, J.-S., Yuan, C.-W., Liu, X.-F., Hu, Z.-C., Yang, W.-Z., Yin, G.-W., Huang, J.-H., Ge, N.-J., Qi, X.-L., Zhao, Y., Zhou, J.-W., Xu, G.-H., Tu, Q., Lin, H.-L., Zhang, Y.-J., Jiang, H., Shao, H.-B., Su, Y.-J., Chen, T.-S., Shi, B.-Q., Xing, W.-G., Gu, S.-Z., Wang, W.-D., Wang, S., Wen, S.-W., Lv, W.-F., Zhu, X., Mu, W., Ren, W.-X., Lu, Z.-M., Fan, Y., Li, J.-P., Zhao, W., Zheng, C.-S., Zhao, X.-Y., Zhao, H., Xu, J., Hu, W.-H., Lei, Y.-M., Wu, Q.-H., Niu, H.-Z., Li, J.-R., Han, J.-J., Feng, D.-P., Cai, Z., Li, Q.-D., Dai, Z.-Y., Shi, R.-S., Chen, Y., Wang, W.-J., Yin, L.-N., Zhou, X., Zhao, H.-T., Zhu, H.-D., Ren, Z.-G., & Teng, G.-J.
- Venue
- eClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 72
- Pages
- 102622
- ISSN
- 2589-5370 (ISSN-L)
- OpenAlex
- W4396683758
- Cited by
- 161
- References
- 11
- FWCI
- 35.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. https://app.cochat.ai/papers/10.1016/j.eclinm.2024.102622
- The paper
- Jin, Z.-C., Chen, J.-J., Zhu, X.-L., Duan, X.-H., Xin, Y.-J., Zhong, B.-Y., Chen, J.-Z., Tie, J., Zhu, K.-S., Zhang, L., Huang, M., Piao, M.-J., Li, X., Shi, H.-B., Liu, R.-B., Xu, A.-B., Ji, F., Wu, J.-B., Shao, G.-L., . . . Teng, G.-J. (2024). Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2024.102622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.